CMS Payment Methodology Inflates Medicare Part B Costs for Stelara Biosimilars
CMS's current inclusion of noncovered self-administered drug prices in Medicare Part B payment calculations inflates costs for Stelara biosimilars. OIG recommends revising pricing methodology to achieve savings.